Canagliflozin, an SGLT2 inhibitor, is an approved and widely used medication in the treatment of type 2 diabetes targeting the gene SLC5A1. However, it was noted that it reduced systolic BP in individuals with type 2 diabetes and chronic kidney disease, providing end-organ protection for this cohort of patients who experience a high burden of hypertension (Ye et al., 2021). This evidence concerns the gene SLC5A1 and type 2 diabetes mellitus.